Search tips
Search criteria 


Logo of bmcmicrBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Microbiology
BMC Microbiol. 2012; 12: 145.
Published online Jul 23, 2012. doi:  10.1186/1471-2180-12-145
PMCID: PMC3416647
Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia
Arianna Pompilio,1,2 Valentina Crocetta,1,2 Marco Scocchi,3 Stefano Pomponio,1,2 Valentina Di Vincenzo,1,2 Mario Mardirossian,3 Giovanni Gherardi,4 Ersilia Fiscarelli,5 Giordano Dicuonzo,4 Renato Gennaro,3 and Giovanni Di Bonaventuracorresponding author1,2
1Department of Biomedical Sciences, “G. d’Annunzio” University of Chieti, Via Vestini 31, 66100 Chieti, Italy
2Center of Excellence on Aging, “G. d'Annunzio” University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
3Department of Life Sciences, University of Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy
4Center for Integrated Research, “Campus Biomedico” University, Via A. Del Portillo, 00128 Rome, Italy
5"Bambino Gesù" Children's Hospital and Research Institute, Piazza Sant’Onofrio 4, 00165 Rome, Italy
corresponding authorCorresponding author.
Arianna Pompilio: ariannapompilio/at/; Valentina Crocetta: vale.crocetta/at/; Marco Scocchi: Mmscocchi/at/; Stefano Pomponio: stefanopomponio/at/; Valentina Di Vincenzo: valentinadivincenzo/at/; Mario Mardirossian: mario.mardirossian/at/; Giovanni Gherardi: G.Gherardi/at/; Ersilia Fiscarelli: evita.fiscarelli/at/; Giordano Dicuonzo: G.Dicuonzo/at/; Renato Gennaro: rgennaro/at/; Giovanni Di Bonaventura: gdibonaventura/at/
Received March 13, 2012; Accepted July 23, 2012.
Treatment of cystic fibrosis-associated lung infections is hampered by the presence of multi-drug resistant pathogens, many of which are also strong biofilm producers. Antimicrobial peptides, essential components of innate immunity in humans and animals, exhibit relevant in vitro antimicrobial activity although they tend not to select for resistant strains.
Three α-helical antimicrobial peptides, BMAP-27 and BMAP-28 of bovine origin, and the artificial P19(9/B) peptide were tested, comparatively to Tobramycin, for their in vitro antibacterial and anti-biofilm activity against 15 Staphylococcus aureus, 25 Pseudomonas aeruginosa, and 27 Stenotrophomonas maltophilia strains from cystic fibrosis patients. All assays were carried out in physical-chemical experimental conditions simulating a cystic fibrosis lung. All peptides showed a potent and rapid bactericidal activity against most P. aeruginosa, S. maltophilia and S. aureus strains tested, at levels generally higher than those exhibited by Tobramycin and significantly reduced biofilm formation of all the bacterial species tested, although less effectively than Tobramycin did. On the contrary, the viability-reducing activity of antimicrobial peptides against preformed P. aeruginosa biofilms was comparable to and, in some cases, higher than that showed by Tobramycin.
The activity shown by α-helical peptides against planktonic and biofilm cells makes them promising “lead compounds” for future development of novel drugs for therapeutic treatment of cystic fibrosis lung disease.
Keywords: Cystic fibrosis, Antimicrobial peptides, Biofilm
Articles from BMC Microbiology are provided here courtesy of
BioMed Central